Stem definition | Drug id | CAS RN |
---|---|---|
1920 | 54-11-5 |
Dose | Unit | Route |
---|---|---|
30 | mg | Chewing gum |
60 | mg | Inhal |
30 | mg | N |
30 | mg | SL |
14 | mg | TD |
Property | Value | Reference |
---|---|---|
BDDCS (Biopharmaceutical Drug Disposition Classification System) | 1 | Benet LZ, Broccatelli F, Oprea TI |
EoM (Fraction excreted unchanged in urine) | 16.70 % | Benet LZ, Broccatelli F, Oprea TI |
MRTD (Maximum Recommended Therapeutic Daily Dose) | 3.52 µM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
BA (Bioavailability) | 30 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
Vd (Volume of distribution) | 2.60 L/kg | Lombardo F, Berellini G, Obach RS |
CL (Clearance) | 18 mL/min/kg | Lombardo F, Berellini G, Obach RS |
fu (Fraction unbound in plasma) | 0.95 % | Lombardo F, Berellini G, Obach RS |
t_half (Half-life) | 2 hours | Lombardo F, Berellini G, Obach RS |
Date | Agency | Company | Orphan |
---|---|---|---|
Nov. 7, 1991 | FDA | SANOFI AVENTIS US |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Nicotine dependence | 541.27 | 13.13 | 101 | 14640 | 535 | 53333790 |
Drug withdrawal syndrome neonatal | 278.99 | 13.13 | 73 | 14668 | 2077 | 53332248 |
Drug dependence | 256.29 | 13.13 | 123 | 14618 | 21349 | 53312976 |
Macular degeneration | 241.42 | 13.13 | 100 | 14641 | 12261 | 53322064 |
Foetal exposure during pregnancy | 208.55 | 13.13 | 126 | 14615 | 34589 | 53299736 |
Incorrect product administration duration | 207.63 | 13.13 | 86 | 14655 | 10538 | 53323787 |
Premature delivery | 205.52 | 13.13 | 113 | 14628 | 25991 | 53308334 |
Product adhesion issue | 173.33 | 13.13 | 63 | 14678 | 5434 | 53328891 |
Overdose | 170.84 | 13.13 | 178 | 14563 | 107558 | 53226767 |
Maternal exposure during pregnancy | 145.10 | 13.13 | 196 | 14545 | 155443 | 53178882 |
Myocardial stunning | 100.56 | 13.13 | 20 | 14721 | 155 | 53334170 |
Intentional product misuse | 84.29 | 13.13 | 85 | 14656 | 49307 | 53285018 |
Application site erythema | 82.17 | 13.13 | 36 | 14705 | 5055 | 53329270 |
Jaundice neonatal | 80.30 | 13.13 | 23 | 14718 | 921 | 53333404 |
Accidental overdose | 80.24 | 13.13 | 58 | 14683 | 21421 | 53312904 |
Dependence | 76.78 | 13.13 | 27 | 14714 | 2114 | 53332211 |
Application site pruritus | 72.39 | 13.13 | 31 | 14710 | 4118 | 53330207 |
Necrosis ischaemic | 68.93 | 13.13 | 20 | 14721 | 839 | 53333486 |
Rhesus incompatibility | 67.29 | 13.13 | 13 | 14728 | 85 | 53334240 |
Drug abuse | 66.26 | 13.13 | 86 | 14655 | 65440 | 53268885 |
Exposure during pregnancy | 65.59 | 13.13 | 121 | 14620 | 124739 | 53209586 |
Poor feeding infant | 64.80 | 13.13 | 15 | 14726 | 252 | 53334073 |
Premature baby | 63.96 | 13.13 | 49 | 14692 | 19752 | 53314573 |
Rheumatoid arthritis | 62.49 | 13.13 | 7 | 14734 | 314524 | 53019801 |
Product quality issue | 61.85 | 13.13 | 63 | 14678 | 36960 | 53297365 |
Pneumonia streptococcal | 58.54 | 13.13 | 21 | 14720 | 1742 | 53332583 |
Oligohydramnios | 55.33 | 13.13 | 29 | 14712 | 6047 | 53328278 |
Beta haemolytic streptococcal infection | 52.08 | 13.13 | 20 | 14721 | 2007 | 53332318 |
Maternal exposure during breast feeding | 51.40 | 13.13 | 23 | 14718 | 3394 | 53330931 |
Tobacco abuse | 46.47 | 13.13 | 14 | 14727 | 670 | 53333655 |
Low birth weight baby | 45.92 | 13.13 | 26 | 14715 | 6311 | 53328014 |
Rib deformity | 43.03 | 13.13 | 10 | 14731 | 171 | 53334154 |
Chronic obstructive pulmonary disease | 42.34 | 13.13 | 67 | 14674 | 61006 | 53273319 |
Exposure via breast milk | 42.17 | 13.13 | 16 | 14725 | 1554 | 53332771 |
Treatment noncompliance | 39.20 | 13.13 | 47 | 14694 | 32988 | 53301337 |
Application site rash | 36.92 | 13.13 | 17 | 14724 | 2679 | 53331646 |
Congenital tricuspid valve incompetence | 36.84 | 13.13 | 8 | 14733 | 99 | 53334226 |
Application site reaction | 36.50 | 13.13 | 12 | 14729 | 765 | 53333560 |
Anxiety | 34.47 | 13.13 | 126 | 14615 | 196578 | 53137747 |
Congenital pulmonary hypertension | 33.33 | 13.13 | 7 | 14734 | 73 | 53334252 |
Substance abuse | 31.38 | 13.13 | 18 | 14723 | 4476 | 53329849 |
Reversible cerebral vasoconstriction syndrome | 30.26 | 13.13 | 14 | 14727 | 2231 | 53332094 |
Developmental hip dysplasia | 30.20 | 13.13 | 12 | 14729 | 1318 | 53333007 |
Premature separation of placenta | 29.47 | 13.13 | 13 | 14728 | 1854 | 53332471 |
Toxicity to various agents | 29.13 | 13.13 | 129 | 14612 | 219469 | 53114856 |
Agitation neonatal | 28.30 | 13.13 | 9 | 14732 | 516 | 53333809 |
Caesarean section | 28.05 | 13.13 | 29 | 14712 | 17291 | 53317034 |
Maternal drugs affecting foetus | 27.89 | 13.13 | 18 | 14723 | 5528 | 53328797 |
Dysmetropsia | 27.57 | 13.13 | 6 | 14735 | 75 | 53334250 |
Loss of proprioception | 26.90 | 13.13 | 8 | 14733 | 366 | 53333959 |
Fatigue | 26.61 | 13.13 | 108 | 14633 | 730398 | 52603927 |
Alopecia | 26.52 | 13.13 | 16 | 14725 | 234567 | 53099758 |
Application site irritation | 26.30 | 13.13 | 12 | 14729 | 1852 | 53332473 |
Axonal neuropathy | 25.95 | 13.13 | 10 | 14731 | 1013 | 53333312 |
Nasal obstruction | 25.40 | 13.13 | 10 | 14731 | 1072 | 53333253 |
Xanthogranuloma | 25.11 | 13.13 | 4 | 14737 | 6 | 53334319 |
Reversible airways obstruction | 24.86 | 13.13 | 10 | 14731 | 1134 | 53333191 |
Throat clearing | 24.85 | 13.13 | 10 | 14731 | 1135 | 53333190 |
Arthropathy | 23.84 | 13.13 | 5 | 14736 | 141448 | 53192877 |
Application site swelling | 23.53 | 13.13 | 8 | 14733 | 566 | 53333759 |
Abnormal dreams | 23.31 | 13.13 | 21 | 14720 | 10580 | 53323745 |
Off label use | 23.26 | 13.13 | 61 | 14680 | 472151 | 52862174 |
Symphysiolysis | 23.24 | 13.13 | 4 | 14737 | 12 | 53334313 |
Premature labour | 22.41 | 13.13 | 22 | 14719 | 12340 | 53321985 |
Drug intolerance | 21.87 | 13.13 | 15 | 14726 | 205478 | 53128847 |
Application site dermatitis | 21.59 | 13.13 | 6 | 14735 | 215 | 53334110 |
Abortion induced | 21.00 | 13.13 | 20 | 14721 | 10806 | 53323519 |
Joint swelling | 20.23 | 13.13 | 21 | 14720 | 234617 | 53099708 |
Pain | 20.14 | 13.13 | 89 | 14652 | 588309 | 52746016 |
Irritability | 20.13 | 13.13 | 33 | 14708 | 30920 | 53303405 |
Respiratory failure | 19.83 | 13.13 | 67 | 14674 | 100445 | 53233880 |
Cardiac death | 19.80 | 13.13 | 7 | 14734 | 556 | 53333769 |
Application site vesicles | 19.15 | 13.13 | 9 | 14732 | 1485 | 53332840 |
Treatment failure | 18.85 | 13.13 | 6 | 14735 | 128397 | 53205928 |
Pre-eclampsia | 18.75 | 13.13 | 17 | 14724 | 8630 | 53325695 |
Therapeutic product effect decreased | 18.22 | 13.13 | 6 | 14735 | 125649 | 53208676 |
Systemic lupus erythematosus | 18.16 | 13.13 | 6 | 14735 | 125408 | 53208917 |
Oophoritis | 18.10 | 13.13 | 4 | 14737 | 54 | 53334271 |
Drug screen positive | 18.08 | 13.13 | 12 | 14729 | 3860 | 53330465 |
Arthralgia | 17.92 | 13.13 | 62 | 14679 | 439721 | 52894604 |
Nightmare | 17.46 | 13.13 | 23 | 14718 | 17728 | 53316597 |
Withdrawal syndrome | 17.44 | 13.13 | 24 | 14717 | 19277 | 53315048 |
Application site pain | 17.24 | 13.13 | 12 | 14729 | 4171 | 53330154 |
Prinzmetal angina | 17.22 | 13.13 | 7 | 14734 | 816 | 53333509 |
Selective eating disorder | 16.85 | 13.13 | 9 | 14732 | 1949 | 53332376 |
Megacolon | 16.81 | 13.13 | 9 | 14732 | 1957 | 53332368 |
Foetal distress syndrome | 16.76 | 13.13 | 8 | 14733 | 1367 | 53332958 |
Application site burn | 16.69 | 13.13 | 7 | 14734 | 883 | 53333442 |
Loss of consciousness | 16.58 | 13.13 | 69 | 14672 | 114143 | 53220182 |
Application site scar | 16.40 | 13.13 | 5 | 14736 | 249 | 53334076 |
Tobacco poisoning | 16.13 | 13.13 | 4 | 14737 | 91 | 53334234 |
Sneezing | 15.98 | 13.13 | 20 | 14721 | 14652 | 53319673 |
Schizoaffective disorder | 15.95 | 13.13 | 9 | 14732 | 2168 | 53332157 |
Full blood count abnormal | 15.75 | 13.13 | 11 | 14730 | 3844 | 53330481 |
False positive investigation result | 15.50 | 13.13 | 6 | 14735 | 615 | 53333710 |
Foetal growth restriction | 15.36 | 13.13 | 14 | 14727 | 7160 | 53327165 |
Suicidal ideation | 15.32 | 13.13 | 44 | 14697 | 60467 | 53273858 |
Drug abuser | 15.28 | 13.13 | 10 | 14731 | 3143 | 53331182 |
Patent ductus arteriosus | 15.10 | 13.13 | 11 | 14730 | 4107 | 53330218 |
Tobacco interaction | 14.78 | 13.13 | 3 | 14738 | 26 | 53334299 |
Pyrexia | 14.37 | 13.13 | 60 | 14681 | 403133 | 52931192 |
Contraindicated product administered | 14.29 | 13.13 | 10 | 14731 | 135619 | 53198706 |
Nervousness | 14.27 | 13.13 | 28 | 14713 | 30150 | 53304175 |
Infection | 14.18 | 13.13 | 16 | 14725 | 172189 | 53162136 |
Gastric dilatation | 13.69 | 13.13 | 6 | 14735 | 842 | 53333483 |
Plethysmography | 13.68 | 13.13 | 3 | 14738 | 39 | 53334286 |
Application site warmth | 13.67 | 13.13 | 4 | 14737 | 173 | 53334152 |
Drug withdrawal syndrome | 13.25 | 13.13 | 26 | 14715 | 27996 | 53306329 |
Hallucination, synaesthetic | 13.22 | 13.13 | 3 | 14738 | 46 | 53334279 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Nicotine dependence | 380.93 | 13.47 | 77 | 12154 | 461 | 32500834 |
Drug withdrawal syndrome neonatal | 286.05 | 13.47 | 89 | 12142 | 3475 | 32497820 |
Drug dependence | 270.32 | 13.47 | 145 | 12086 | 23339 | 32477956 |
Incorrect product administration duration | 228.67 | 13.47 | 79 | 12152 | 4299 | 32496996 |
Foetal exposure during pregnancy | 213.26 | 13.47 | 153 | 12078 | 41148 | 32460147 |
Intentional product misuse | 166.70 | 13.47 | 125 | 12106 | 35926 | 32465369 |
Accidental overdose | 136.42 | 13.47 | 87 | 12144 | 19252 | 32482043 |
Overdose | 130.40 | 13.47 | 162 | 12069 | 86915 | 32414380 |
Product adhesion issue | 121.15 | 13.47 | 38 | 12193 | 1521 | 32499774 |
Maternal exposure during breast feeding | 102.98 | 13.47 | 34 | 12197 | 1606 | 32499689 |
Premature baby | 96.34 | 13.47 | 69 | 12162 | 18449 | 32482846 |
Low birth weight baby | 74.29 | 13.47 | 41 | 12190 | 6953 | 32494342 |
Dependence | 70.82 | 13.47 | 24 | 12207 | 1229 | 32500066 |
Jaundice neonatal | 68.28 | 13.47 | 23 | 12208 | 1156 | 32500139 |
Alcohol abuse | 66.94 | 13.47 | 33 | 12198 | 4439 | 32496856 |
Exposure via breast milk | 62.30 | 13.47 | 24 | 12207 | 1778 | 32499517 |
Toxicity to various agents | 61.51 | 13.47 | 176 | 12055 | 177865 | 32323430 |
Foetal disorder | 60.79 | 13.47 | 19 | 12212 | 751 | 32500544 |
Tobacco poisoning | 53.15 | 13.47 | 9 | 12222 | 15 | 32501280 |
Neutropenia neonatal | 50.82 | 13.47 | 16 | 12215 | 648 | 32500647 |
Drug abuser | 48.52 | 13.47 | 26 | 12205 | 4158 | 32497137 |
Drug screen positive | 48.19 | 13.47 | 26 | 12205 | 4215 | 32497080 |
Alcohol interaction | 46.95 | 13.47 | 21 | 12210 | 2268 | 32499027 |
Tremor neonatal | 44.53 | 13.47 | 13 | 12218 | 406 | 32500889 |
Poor feeding infant | 42.49 | 13.47 | 13 | 12218 | 478 | 32500817 |
Body temperature abnormal | 37.05 | 13.47 | 12 | 12219 | 533 | 32500762 |
Foetal distress syndrome | 35.86 | 13.47 | 14 | 12217 | 1075 | 32500220 |
Application site pruritus | 35.85 | 13.47 | 15 | 12216 | 1378 | 32499917 |
Substance abuse | 35.84 | 13.47 | 26 | 12205 | 7081 | 32494214 |
Breech presentation | 35.33 | 13.47 | 9 | 12222 | 166 | 32501129 |
Drug abuse | 34.35 | 13.47 | 86 | 12145 | 80157 | 32421138 |
Tobacco abuse | 31.93 | 13.47 | 10 | 12221 | 398 | 32500897 |
Drug use disorder | 29.84 | 13.47 | 18 | 12213 | 3603 | 32497692 |
Withdrawal syndrome | 29.23 | 13.47 | 29 | 12202 | 12093 | 32489202 |
Off label use | 29.08 | 13.47 | 44 | 12187 | 306276 | 32195019 |
Application site erythema | 28.40 | 13.47 | 15 | 12216 | 2328 | 32498967 |
Schizophrenia | 28.08 | 13.47 | 26 | 12205 | 9958 | 32491337 |
Laryngeal dysplasia | 27.54 | 13.47 | 4 | 12227 | 0 | 32501295 |
Application site reaction | 26.95 | 13.47 | 9 | 12222 | 440 | 32500855 |
Agitation neonatal | 25.48 | 13.47 | 11 | 12220 | 1091 | 32500204 |
Tobacco user | 25.09 | 13.47 | 9 | 12222 | 546 | 32500749 |
Drug withdrawal syndrome | 24.53 | 13.47 | 34 | 12197 | 20197 | 32481098 |
Product quality issue | 24.34 | 13.47 | 33 | 12198 | 19200 | 32482095 |
Tachycardia | 23.26 | 13.47 | 74 | 12157 | 79014 | 32422281 |
Venolymphatic malformation | 23.24 | 13.47 | 5 | 12226 | 42 | 32501253 |
Application site rash | 21.42 | 13.47 | 9 | 12222 | 835 | 32500460 |
Treatment noncompliance | 20.82 | 13.47 | 37 | 12194 | 27165 | 32474130 |
Acne infantile | 20.18 | 13.47 | 5 | 12226 | 82 | 32501213 |
Diarrhoea | 19.62 | 13.47 | 71 | 12160 | 364731 | 32136564 |
Renal hypoplasia | 19.54 | 13.47 | 5 | 12226 | 94 | 32501201 |
Application site scar | 19.11 | 13.47 | 4 | 12227 | 29 | 32501266 |
Renal impairment | 18.12 | 13.47 | 6 | 12225 | 91966 | 32409329 |
Pulmonary valve stenosis congenital | 17.48 | 13.47 | 5 | 12226 | 145 | 32501150 |
Application site vesicles | 17.29 | 13.47 | 7 | 12224 | 591 | 32500704 |
Myoclonic epilepsy | 17.01 | 13.47 | 8 | 12223 | 970 | 32500325 |
Weight decrease neonatal | 16.85 | 13.47 | 6 | 12225 | 356 | 32500939 |
Breathing-related sleep disorder | 16.39 | 13.47 | 5 | 12226 | 182 | 32501113 |
Anxiety | 15.99 | 13.47 | 75 | 12156 | 95930 | 32405365 |
Palpitations | 15.84 | 13.47 | 39 | 12192 | 35930 | 32465365 |
Application site urticaria | 15.74 | 13.47 | 4 | 12227 | 73 | 32501222 |
Antipsychotic drug level increased | 15.70 | 13.47 | 12 | 12219 | 3534 | 32497761 |
Euphoric mood | 15.45 | 13.47 | 14 | 12217 | 5213 | 32496082 |
Application site discolouration | 15.20 | 13.47 | 5 | 12226 | 233 | 32501062 |
Application site pain | 15.09 | 13.47 | 9 | 12222 | 1765 | 32499530 |
Drug tolerance increased | 15.07 | 13.47 | 6 | 12225 | 485 | 32500810 |
Insomnia | 14.99 | 13.47 | 76 | 12155 | 100272 | 32401023 |
Necrotising ulcerative gingivostomatitis | 14.95 | 13.47 | 4 | 12227 | 90 | 32501205 |
Death | 14.83 | 13.47 | 84 | 12147 | 382433 | 32118862 |
Knee deformity | 14.47 | 13.47 | 6 | 12225 | 539 | 32500756 |
Nightmare | 14.30 | 13.47 | 21 | 12210 | 13145 | 32488150 |
Neonatal disorder | 14.11 | 13.47 | 7 | 12224 | 954 | 32500341 |
Emphysema | 14.10 | 13.47 | 18 | 12213 | 9879 | 32491416 |
Potentiating drug interaction | 14 | 13.47 | 13 | 12218 | 4995 | 32496300 |
Left ventricular hypertrophy | 13.95 | 13.47 | 15 | 12216 | 6865 | 32494430 |
Facial asymmetry | 13.89 | 13.47 | 5 | 12226 | 306 | 32500989 |
Rhesus incompatibility | 13.76 | 13.47 | 3 | 12228 | 27 | 32501268 |
Maternal drugs affecting foetus | 13.73 | 13.47 | 12 | 12219 | 4265 | 32497030 |
Source | Code | Description |
---|---|---|
ATC | N07BA01 | NERVOUS SYSTEM OTHER NERVOUS SYSTEM DRUGS DRUGS USED IN ADDICTIVE DISORDERS Drugs used in nicotine dependence |
FDA CS | M0014836 | Nicotine |
MeSH PA | D018678 | Cholinergic Agents |
MeSH PA | D018679 | Cholinergic Agonists |
MeSH PA | D005731 | Ganglionic Stimulants |
MeSH PA | D018377 | Neurotransmitter Agents |
MeSH PA | D018722 | Nicotinic Agonists |
MeSH PA | D018373 | Peripheral Nervous System Agents |
MeSH PA | D000077444 | Smoking Cessation Agents |
FDA EPC | N0000175706 | Cholinergic Nicotinic Agonist |
CHEBI has role | CHEBI:22917 | botanical insecticides |
CHEBI has role | CHEBI:35471 | psychopharmaceuticals |
CHEBI has role | CHEBI:35474 | minor tranquilisers |
CHEBI has role | CHEBI:35703 | Xenobiotic |
CHEBI has role | CHEBI:47958 | muscarinic agonists |
CHEBI has role | CHEBI:49110 | peripheral nervous system agent |
CHEBI has role | CHEBI:50846 | Biomodulator |
CHEBI has role | CHEBI:50905 | teratogen |
CHEBI has role | CHEBI:50910 | agente neurotoxico |
CHEBI has role | CHEBI:52290 | mitogens |
CHEBI has role | CHEBI:59163 | biological marker |
CHEBI has role | CHEBI:76924 | plant metabolites |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Nicotine dependence | indication | 56294008 | DOID:0050742 |
Smoking cessation assistance | indication | 384742004 | |
Pellagra | indication | 418186002 | DOID:8457 |
Niacin deficiency | indication | 418279001 | |
Nicotine Withdrawal Symptoms | indication | ||
Hyperlipidemia | off-label use | 55822004 | DOID:1168 |
Hypophosphatemia | contraindication | 4996001 | |
Alcoholism | contraindication | 7200002 | |
Peptic ulcer | contraindication | 13200003 | DOID:750 |
Esophagitis | contraindication | 16761005 | DOID:11963 |
Myocardial infarction | contraindication | 22298006 | DOID:5844 |
Hyperthyroidism | contraindication | 34486009 | DOID:7998 |
Temporomandibular joint disorder | contraindication | 41888000 | |
Low blood pressure | contraindication | 45007003 | |
Diabetes mellitus type 1 | contraindication | 46635009 | DOID:9744 |
Thromboangiitis obliterans | contraindication | 52403007 | DOID:12918 |
Blood coagulation disorder | contraindication | 64779008 | DOID:1247 |
Diabetes mellitus | contraindication | 73211009 | DOID:9351 |
Hyperglycemia | contraindication | 80394007 | DOID:4195 |
Prinzmetal angina | contraindication | 87343002 | |
Gout | contraindication | 90560007 | DOID:13189 |
Magnetic resonance imaging | contraindication | 113091000 | |
Liver function tests abnormal | contraindication | 166603001 | |
Angina pectoris | contraindication | 194828000 | |
Arterial hemorrhage | contraindication | 234003006 | |
Disease of liver | contraindication | 235856003 | DOID:409 |
Raynaud's phenomenon | contraindication | 266261006 | |
Pregnancy, function | contraindication | 289908002 | |
Thrombocytopenic disorder | contraindication | 302215000 | DOID:1588 |
Pheochromocytoma | contraindication | 302835009 | |
Acute coronary syndrome | contraindication | 394659003 | |
Pharyngitis | contraindication | 405737000 | DOID:2275 |
Disorder of coronary artery | contraindication | 414024009 | |
Myocardial infarction in recovery phase | contraindication | 418044006 | |
Hypertensive urgency | contraindication | 443482000 | |
Life-Threatening Cardiac Arrhythmias | contraindication |
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 9.05 | Basic |
pKa2 | 3.14 | Basic |
None
None
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
Neuronal acetylcholine receptor; alpha4/beta2 | Ion channel | AGONIST | Ki | 8.56 | WOMBAT-PK | CHEMBL | |||
Potassium voltage-gated channel subfamily D member 3 | Ion channel | IC50 | 7.40 | WOMBAT-PK | |||||
Cytochrome P450 2A6 | Enzyme | IC50 | 5.36 | WOMBAT-PK | |||||
Transient receptor potential cation channel subfamily A member 1 | Ion channel | ACTIVATOR | EC50 | 4.80 | IUPHAR | ||||
Neuronal acetylcholine receptor; alpha2/beta4 | Ion channel | Ki | 7.15 | CHEMBL | |||||
Neuronal acetylcholine receptor; alpha2/beta2 | Ion channel | Ki | 8.26 | CHEMBL | |||||
Neuronal acetylcholine receptor; alpha3/beta4 | Ion channel | Ki | 5.95 | WOMBAT-PK | |||||
Neuronal acetylcholine receptor; alpha3/beta2 | Ion channel | Ki | 7.85 | WOMBAT-PK | |||||
Neuronal acetylcholine receptor; alpha4/beta4 | Ion channel | Ki | 7.64 | CHEMBL | |||||
Serotonin 3 (5-HT3) receptor | Ion channel | Ki | 4.15 | CHEMBL | |||||
Acetylcholine receptor; alpha1/beta1/delta/gamma | Ion channel | Ki | 5.83 | CHEMBL | |||||
Neuronal acetylcholine receptor; alpha3/alpha6/beta2/beta3 | Ion channel | IC50 | 7.07 | CHEMBL | |||||
Acetylcholine receptor subunit alpha | Ion channel | IC50 | 4.68 | CHEMBL | |||||
Neuronal acetylcholine receptor subunit alpha-3 | Ion channel | IC50 | 7.35 | CHEMBL | |||||
Neuronal acetylcholine receptor subunit alpha-7 | Ion channel | Ki | 5.39 | WOMBAT-PK | |||||
Acetylcholine-binding protein | Unclassified | Ki | 7.20 | CHEMBL | |||||
Acetylcholine receptor subunit delta | Ion channel | Ki | 9 | CHEMBL | |||||
Neuronal acetylcholine receptor subunit alpha-4 | Ion channel | Ki | 9.03 | CHEMBL | |||||
Neuronal acetylcholine receptor subunit alpha-7 | Ion channel | Ki | 6.89 | CHEMBL | |||||
Neuronal acetylcholine receptor subunit alpha-7 | Ion channel | Ki | 6.61 | CHEMBL | |||||
Neuronal acetylcholine receptor subunit alpha-9 | Ion channel | Kd | 8.30 | CHEMBL | |||||
Neuronal acetylcholine receptor subunit beta-4 | Ion channel | Ki | 7.14 | CHEMBL | |||||
Neuronal acetylcholine receptor subunit alpha-3 | Ion channel | Ki | 7.33 | CHEMBL | |||||
Neuronal acetylcholine receptor subunit alpha-2 | Ion channel | Ki | 7.92 | CHEMBL | |||||
Soluble acetylcholine receptor | Unclassified | Ki | 7.52 | CHEMBL | |||||
Acetylcholine receptor subunit alpha | Ion channel | IC50 | 4.64 | CHEMBL | |||||
Lycopene cyclase | Enzyme | IC50 | 5.32 | CHEMBL | |||||
Nicotinic acetylcholine receptor alpha 5 subunit | Ion channel | Ki | 5.61 | CHEMBL | |||||
Acetylcholine receptor subunit beta-like 2 | Ion channel | Ki | 5.57 | CHEMBL | |||||
Neuronal acetylcholine receptor subunit alpha-4 | Ion channel | Ki | 8.72 | CHEMBL | |||||
Neuronal acetylcholine receptor subunit alpha-4 | Ion channel | IC50 | 8.15 | CHEMBL | |||||
Neuronal acetylcholine receptor; alpha2/beta2 | Ion channel | Ki | 8.26 | CHEMBL | |||||
Neuronal acetylcholine receptor; alpha3/beta2 | Ion channel | Ki | 9 | CHEMBL | |||||
Neuronal acetylcholine receptor; alpha3/beta4 | Ion channel | Ki | 6.70 | CHEMBL | |||||
Neuronal acetylcholine receptor; alpha4/beta2 | Ion channel | Kd | 9.40 | CHEMBL | |||||
Neuronal acetylcholine receptor; alpha4/beta4 | Ion channel | Ki | 8.26 | CHEMBL | |||||
Neuronal acetylcholine receptor | Ion channel | Kd | 11 | CHEMBL | |||||
Neuronal acetylcholine receptor; alpha2/beta4 | Ion channel | Ki | 7.15 | CHEMBL | |||||
Acetylcholine receptor | Ion channel | Ki | 5.20 | CHEMBL | |||||
Muscarinic acetylcholine receptor | GPCR | IC50 | 4.55 | CHEMBL | |||||
Transient receptor potential cation channel subfamily A member 1 | Ion channel | EC50 | 5 | CHEMBL | |||||
Potassium voltage-gated channel subfamily D member 3 | Ion channel | BLOCKER | IC50 | 7.40 | IUPHAR |
ID | Source |
---|---|
4020286 | VUID |
N0000148163 | NUI |
D03365 | KEGG_DRUG |
65-31-6 | SECONDARY_CAS_RN |
4018610 | VANDF |
4020286 | VANDF |
C0028040 | UMLSCUI |
CHEBI:17688 | CHEBI |
NCT | PDB_CHEM_ID |
CHEMBL3 | ChEMBL_ID |
DB00184 | DRUGBANK_ID |
D009538 | MESH_DESCRIPTOR_UI |
89594 | PUBCHEM_CID |
2585 | IUPHAR_LIGAND_ID |
6M3C89ZY6R | UNII |
1306106 | RXNORM |
11529 | MMSL |
5173 | MMSL |
5174 | MMSL |
72003 | MMSL |
d00316 | MMSL |
001770 | NDDF |
003575 | NDDF |
323283001 | SNOMEDCT_US |
68540007 | SNOMEDCT_US |
77544001 | SNOMEDCT_US |
D061485 | MESH_DESCRIPTOR_UI |
CHEMBL1201536 | ChEMBL_ID |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
Nicotrol | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0009-5400 | INHALANT | 4 mg | RESPIRATORY (INHALATION) | NDA | 29 sections |
Nicotrol | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0009-5401 | SPRAY, METERED | 10 mg | NASAL | NDA | 28 sections |
Good Sense Nicotine | HUMAN OTC DRUG LABEL | 1 | 0113-0029 | GUM, CHEWING | 2 mg | ORAL | ANDA | 15 sections |
Good Sense Nicotine | HUMAN OTC DRUG LABEL | 1 | 0113-0053 | GUM, CHEWING | 4 mg | ORAL | ANDA | 15 sections |
Good Sense Nicotine | HUMAN OTC DRUG LABEL | 1 | 0113-0170 | GUM, CHEWING | 4 mg | ORAL | ANDA | 15 sections |
good sense nicotinemint | HUMAN OTC DRUG LABEL | 1 | 0113-0206 | GUM, CHEWING | 2 mg | ORAL | ANDA | 15 sections |
Good Sense Nicotine | HUMAN OTC DRUG LABEL | 1 | 0113-0344 | LOZENGE | 2 mg | ORAL | ANDA | 15 sections |
Good Sense Nicotine | HUMAN OTC DRUG LABEL | 1 | 0113-0422 | GUM, CHEWING | 4 mg | ORAL | ANDA | 15 sections |
Good Sense Nicotine | HUMAN OTC DRUG LABEL | 1 | 0113-0456 | GUM, CHEWING | 2 mg | ORAL | ANDA | 15 sections |
Good Sense Nicotine | HUMAN OTC DRUG LABEL | 1 | 0113-0532 | GUM, CHEWING | 4 mg | ORAL | ANDA | 15 sections |
basic care nicotine | HUMAN OTC DRUG LABEL | 1 | 0113-0704 | GUM, CHEWING | 2 mg | ORAL | ANDA | 15 sections |
basic care nicotine | HUMAN OTC DRUG LABEL | 1 | 0113-0713 | GUM, CHEWING | 4 mg | ORAL | ANDA | 15 sections |
Good Sense Nicotine | HUMAN OTC DRUG LABEL | 1 | 0113-0734 | LOZENGE | 2 mg | ORAL | ANDA | 15 sections |
basic care nicotine | HUMAN OTC DRUG LABEL | 1 | 0113-0749 | GUM, CHEWING | 4 mg | ORAL | ANDA | 15 sections |
basic care nicotine | HUMAN OTC DRUG LABEL | 1 | 0113-0761 | GUM, CHEWING | 2 mg | ORAL | ANDA | 15 sections |
Good Sense Nicotine | HUMAN OTC DRUG LABEL | 1 | 0113-0854 | GUM, CHEWING | 4 mg | ORAL | ANDA | 15 sections |
good sense nicotine | HUMAN OTC DRUG LABEL | 1 | 0113-0873 | LOZENGE | 4 mg | ORAL | ANDA | 15 sections |
Good Sense Nicotine | HUMAN OTC DRUG LABEL | 1 | 0113-0957 | LOZENGE | 4 mg | ORAL | ANDA | 15 sections |
Good Sense Nicotine | HUMAN OTC DRUG LABEL | 1 | 0113-1125 | LOZENGE | 2 mg | ORAL | ANDA | 15 sections |
good sense nicotine | HUMAN OTC DRUG LABEL | 1 | 0113-1190 | LOZENGE | 4 mg | ORAL | ANDA | 15 sections |
good sense nicotine | HUMAN OTC DRUG LABEL | 1 | 0113-1352 | GUM, CHEWING | 2 mg | ORAL | ANDA | 15 sections |
basic care nicotine | HUMAN OTC DRUG LABEL | 1 | 0113-7007 | LOZENGE | 4 mg | ORAL | ANDA | 14 sections |
basic care nicotine | HUMAN OTC DRUG LABEL | 1 | 0113-7008 | LOZENGE | 2 mg | ORAL | ANDA | 15 sections |
basic care nicotine | HUMAN OTC DRUG LABEL | 1 | 0113-7029 | GUM, CHEWING | 2 mg | ORAL | ANDA | 15 sections |
basic care nicotine | HUMAN OTC DRUG LABEL | 1 | 0113-7124 | LOZENGE | 2 mg | ORAL | ANDA | 15 sections |
basic care nicotine | HUMAN OTC DRUG LABEL | 1 | 0113-7170 | GUM, CHEWING | 4 mg | ORAL | ANDA | 15 sections |
basic care nicotine | HUMAN OTC DRUG LABEL | 1 | 0113-7190 | LOZENGE | 4 mg | ORAL | ANDA | 15 sections |
Basic Care nicotine | HUMAN OTC DRUG LABEL | 1 | 0113-7201 | LOZENGE | 2 mg | ORAL | ANDA | 14 sections |
Basic Care nicotine | HUMAN OTC DRUG LABEL | 1 | 0113-7203 | LOZENGE | 4 mg | ORAL | ANDA | 14 sections |
basic care nicotine | HUMAN OTC DRUG LABEL | 1 | 0113-7344 | LOZENGE | 2 mg | ORAL | ANDA | 15 sections |